CompletedNCT02736383Updated Sep 22, 2023

Tranexamic Acid in Hip Fracture Surgery

An observational study in Hip Fracture, sponsored by Corewell Health West. Completed. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2023-09-22.

Sponsored by Corewell Health West · Observational

Study type: Observational
Model: Cohort
Time perspective: Retrospective
Enrollment: 142
Ages: 65 Years and older
Sex: All

Study summary

To determine if TXA utilization is effective at reducing transfusion rates in elderly patients undergoing surgery for treatment of a hip fractures.

Conditions studied

Hip Fracture

Browse trials for

Hip Fractures 848

In context

Hip Fractures

848 studies on the registry are indexed under Hip Fractures; 160 are open to participants now.

This study's enrollment of 142 is close to the median of 142 across 277 observational studies indexed under Hip Fractures.

Browse Hip Fractures studies →

Lead sponsor

Corewell Health West is the lead sponsor of 16 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 65 Years and older
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Non-probability sample

Study population

Patients with hip fractures

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Acute, isolated, unilateral femoral neck, intertrochanteric, and per trochanteric hip fractures confirmed by anteroposterior/lateral hip radiographs, computed tomography, or magnetic resonance imaging.
Age 65 and older
Low energy mechanism of injury
Hip fracture fixation performed within 48 hours
English speaking
Anticipated medical optimization for operative fixation
No other major trauma

Exclusion criteria

Exclusion Criteria:

Retained hardware around the affected hip
Infection around the affected hip
Transfer patients with a length of stay > 24 hours at the transferring hospital
Diagnosis of deficient natural anticoagulation
Known congenital thrombophilia (Deficiency of Protein C, S, Antithrombin)
Known allergy to TXA
Patients undergoing percutaneous pinning of the hip fracture

Study design

Observational model: Cohort
Time perspective: Retrospective
Enrollment: 142 participants (actual)
Patient registry: No

Groups and cohorts

Tranexamic Acid
Patients that receive 2 gm TXA during surgery
No Tranexamic Acid
Patients that receive no TXA during surgery

What researchers measure

Primary outcomes

Blood Transfusion Rate
Blood transfusion rates during the patients hospital stay will be assessed.
Time frame: 6 weeks

Secondary outcomes

Hospital Length of stay
The patients length of stay in the hospital will be determined.
Time frame: 6 weeks
Post operative complications
Post operative complications will be assessed through the 6 weeks.
Time frame: 6 weeks
Hospitalization costs
Economic evaluation for inpatient and re-admission will be assessed.
Time frame: 6 weeks

Study locations

No study locations are listed for this record.

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

Timeline

Tracking since Sep 25, 2026

ElapsedEstimatedEstimated, not yet reached

Ran from May 2016 to primary completion in Jul 2017, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered: Mar 29, 2016
First posted: Apr 13, 2016
StartActual: May 2016
Primary completionActual: Jul 2017
CompletionActual: Jul 2017
Last update: Sep 22, 2023

What these dates mean

Start.: When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.: When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.: When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.: Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.

No changes since tracking began. The registry record was last updated on Sep 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT02736383
Lead sponsor: Corewell Health West
Responsible party: Sponsor
First posted: Apr 13, 2016
Start date: May 2016
Primary completion: Jul 2017
Completion: Jul 2017
Last update: Sep 22, 2023

Study contacts

Blake W Miller, DO

principal investigator · Corewell Health West

Oversight

Data monitoring committee: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Hip Fractures →

Other studies from this sponsor

Corewell Health West

Start the discussion